PROTOCOL

Systemic Anti Cancer Therapy Protocol

Ifosfamide + Mesna and Etoposide Sarcoma

PROTOCOL REF: MPHAIFOETO (Version No.1.2)

Approved for use in:

- 2nd line osteosarcoma
- 2nd line ewings sarcoma
- Other high grade bonesarcomas:

Dosage:

IE							
Drug	Dosage		Days		Administration		
Etoposide	120mg/m ²	D1	D2	D3	Over 2 hours 1000ml Sodium Chloride 0.9%		
Mesna	500mg/m ²	D1	D2	D3	Over 1 hour 500ml Sodium Chloride 0.9%		
lfosfamide + Mesna	3000mg/m ² + 3000mg/m ²	D1	D2	D3	Over 4 hours 1000ml Sodium Chloride 0.9%		
Mesna	3000mg/m ²	D1	D2	D3	Over 8 hours 1000ml Sodium Chloride 0.9%		
Every 3 weeks for 6 cycles							

Issue Date: October 2023 Review Date October 2026	Page 0 of 11	Protocol reference: MPHAIFOET	o
Author: Rob Challoner	Authorised by: Drugs & Therapeutics Committee		Version No: 1.2



Administration & Counselling Points

Ifosfamide

Patients require measurement of their urine phosphate and creatinine prior to each cycle The patient must fast overnight. The following morning, the patient should discard the first urine passed and then collect the second urine.

Patients require dipstick urine monitoring during treatment

Patients must report signs and symptoms of haemorhagic cystitis including blood in urine, pain on urination, abdominal pain, changes to urinary frequency or urgency.

Patients must report signs of encephalopathy including excessive sleepiness, disorientation, confusion or hallucination.

Administration: Ifosfamide

- Record patients weight at the same time each day as well as a strict fluid balance chart.
- If there is a positive fluid balance of 2 litres or more, weight gain of > 2kg or symptoms of fluid overload give furosemide 20mg orally Test urine for microscopic haematuria each cycle (see algorithm)
- Observe for insidious signs of encephalopathy, initially somnolence and confusion (see toxicity management)

Issue Date: October 2023 Review Date October 2026	Page 1 of 11	Protocol reference: MPHAIFOET	D
Author: Rob Challoner	Authorised by: Drugs & Therapeutics Committee		Version No: 1.2

SACT PROTOCOL



Renal Function and Renal Tubular Reabsorption of Phosphate

A significant rise in serum creatinine must be discussed with a consultant even if CrCL >60mL/min discuss with consultant as ifosfamide may cause delayed impairment

Measure serum electrolytes and bicarbonate levels

Measure fasting urine phosphate and creatinine

Assess TmP/GFR (renal tubular resorption of phosphate) using calculator via citrix <u>http://clinicalapps.clatterbridgecc.nhs.uk/RTPR/</u>

Use table below to evaluate renal toxicity

Toxicity grade	GFR mL/min/1.73m2	TpCreat mmol/L	Bicarb*	Action (apply worst grade)		
0 or 1	≥60	≥1.00	≥17.0	Continue ifosfamide at 100% dose		
2	40-59	0.8-0.99	14-16.9	Ifosfamide 70% dose		
3 ≤40 ≤0.80 ≤14.0 Discuss with consultant potential switch to cyclophosphamide** dose 1500mg/m²/d, day 1 only						
*Conside	*Consider potential causes for low HCO ₃ before modifying ifosfamide dose e.g. infection					

Emetogenic risk:

Highly emetogenic.

Supportive treatments:

Metoclopramide 10mg oral tablets up to three times a day if required

Apreptitant prior to chemotherapy – 125mg on day 1 and 80mg on days 2 / 3

Dexamethasone 4mg TWICE daily for THREE days starting day after last IV chemotherapy

Filgrastim SC injection ONCE daily for SEVEN days starting day after last IV chemotherapy

Issue Date: October 2023 Review Date October 2026	Page 2 of 11	Protocol reference: MPHAIFOET	D
Author: Rob Challoner	Authorised by: Drugs & Therapeutics Committee		Version No: 1.2



Extravasation risk:

Etoposide- irritant Ifosfamide- irritant

Refer to the CCC policy for the 'Prevention and Management of Extravasation Injuries'

Dosing in renal and hepatic impairment:

		Creatinine clearance (mL/min)	Dose of etoposide	
	Etoposide	>50	100% of dose	
		10-50	75% dose	
		<15	contraindicated	
Renal		Creatinine clearance (mL/min)	Dose of ifosfamide	
	If a of a second all a	≥60	100%	
	lfosfamide	40-59	70%	
		<40	Clinical decision	
		<15	Contraindicated	

	Etoposide	compromis	is activated in the liver. Severe impairment may be efficacy of treatment. 50 μmol/L consider 50% of the dose, increase if tolerated
Hepatic	lfosfamide	Mild Moderate	No adjustments required
		Severe	Ifosfamide is activated in the liver. Severe impairment may compromise efficacy of treatment.

Mild	Bilirubin >1.0-1.5 x ULN OR AST > ULN		
Moderate	Bilirubin 1.5-3 x ULN		
Severe	Bilirubin >3.0 x ULN		
As classified by Organ Dysfunction Working Group:			

Issue Date: October 2023 Review Date October 2026	Page 3 of 11	Protocol reference: MPHAIFOET	0
Author: Rob Challoner	Authorised by: Drugs & Therapeutics Committee		Version No: 1.2

SACT PROTOCOL



Interactions:

Etoposide

- Concomitant phenytoin therapy is associated with increased etoposide clearance and reduced efficacy, and other enzyme-inducing antiepileptic therapy may be associated with increased etoposide clearance and reduced efficacy.
- Co-administration of antiepileptic drugs and etoposide can lead to decreased seizure control due to pharmacokinetic interactions between the drugs.
- Co-administration of warfarin and etoposide may result in elevated international normalized ratio.
- There is increased risk of fatal systemic vaccinal disease with the use of yellow fever vaccine. Live vaccines are contraindicated in immunosuppressed patients.

<u>Ifosfamide</u>

- Increased haematotoxicity and/or immunosuppression may result from a combined effect of ifosfamide and:
 - ACE inhibitors: ACE inhibitors can cause leukopenia.
 - Carboplatin
- Increased pulmonary toxicity may result from a combined effect of ifosfamide and, for example:
 - Amiodarone
 - G-CSF,
- Increased nephrotoxicity may result from a combined effect of ifosfamide and, for example:
 - Aciclovir
 - Aminoglycosides
- Inhibition of CYP 3A4 can also lead to increased formation of an ifosfamide metabolite associated with CNS and nephrotoxicity. CYP 3A4 inhibitors include:
 - Ketoconazole
 - Fluconazole
- Coumarin derivatives: Increased INR (increased international normalized ratio) has been reported in patients receiving ifosfamide and warfarin.
- Vaccines: The immunosuppressive effects of ifosfamide can be expected to reduce the response to vaccination. Use of live vaccines may lead to vaccine induced infection.
- Please refer to the SPC for more information.

Issue Date: October 2023 Review Date October 2026	Page 4 of 11	Protocol reference: MPHAIFOET	C
Author: Rob Challoner	Authorised by: Drugs & Therapeutics Committee		Version No: 1.2



Treatment schedule:

Day	Drug	Dose	Route	Diluent and rate
	Aprepitant	125mg	PO	30 minutes before chemotherapy
	Dexamethasone	8mg	PO	30 minutes before chemotherapy
	Ondansetron	16mg	PO	30 minutes before chemotherapy
	Etoposide	120 mg/m ²	IV	Sodium Chloride 0.9% 1000mL over 120 minutes
1	Mesna	500mg/m ²	IV	Sodium Chloride 0.9% 500mL over 60 minutes
	Ifosfamide +mesna	3000mg/m ² +3000mg/m ²	IV	Sodium Chloride 0.9% 1000mL over 4 hours
	Mesna	3000mg/m ²	IV	Sodium Chloride 0.9% 1000mL over 8 hours
	Aprepitant	80mg	PO	30 minutes before chemotherapy
	Dexamethasone	8mg	PO	30 minutes before chemotherapy
	Ondansetron	16mg	PO	30 minutes before chemotherapy
2	Etoposide	120 mg/m ² IV		Sodium Chloride 0.9% 1000mL over 120 minutes
	Mesna	500mg/m ²	IV	Sodium Chloride 0.9% 500mL over 60 minutes
	Ifosfamide +mesna	3000mg/m ² +3000mg/m ²	IV	Sodium Chloride 0.9% 1000mL over 4 hours
	Mesna	3000mg/m ² IV		Sodium Chloride 0.9% 1000mL over 8 hours
	Aprepitant	80mg	PO	30 minutes before chemotherapy
	Dexamethasone	8mg	PO	30 minutes before chemotherapy
	Ondansetron	16mg	PO	30 minutes before chemotherapy
	Etoposide	120 mg/m ²	IV	Sodium Chloride 0.9% 1000mL over 120 minutes
3	Mesna	500mg/m ²	IV	Sodium Chloride 0.9% 500mL over 60 minutes
	lfosfamide +mesna	3000mg/m ² +3000mg/m ²	IV	Sodium Chloride 0.9% 1000mL over 4 hours
	Mesna	3000mg/m ²	IV	Sodium Chloride 0.9% 1000mL over 8 hours

Issue Date: October 2023 Review Date October 2026	Page 5 of 11	Protocol reference: MPHAIFOET	D
Author: Rob Challoner	Authorised by: Drugs & Therapeutics Committee		Version No: 1.2

SACT PROTOCOL



Main toxicities:

Etoposide

- Myelosuppression,
- Nausea & vomiting,
- Diarrhoea,
- Mucositis,
- Allergic reactions,
- Alopecia,
- Transient alterations in LFT
- Rarely peripheral neuropathy
- Hypertension

lfosfamide

- Myleosuppression
- Decreased appetite
- Nausea/vomiting
- Hepatotoxicity
- Alopecia
- Renal dysfunction
- Haematuria
- Phlebitis
- Haemorrhagic cystitis

Issue Date: October 2023 Review Date October 2026	Page 6 of 11	Protocol reference: MPHAIFOET	D
Author: Rob Challoner	Authorised by: Drugs & Therapeutics Committee Version No: 1.2		Version No: 1.2





Investigations and treatment plan:

	Pre	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Cycle 5	Cycle 6	Ongoing
Informed Consent	Х							
Clinical Assessment	x					X**		As clinically indicated
SACT Assessment (to include PS and toxicities)	х	х	х	x	х	х	х	Every cycle
FBC	x		x	x	x	x	x	Every cycle
U&E & LFTs & Mg ² Ca ²⁺ ,Cl ⁻ , HCO ₃	Х		x	х	х	x	x	Every Cycle
CrCl (Cockcroft and Gault)	x		x	x	х	x	x	Every cycle
CT scan**	х							At the end of treatment and if clinically indicated
ECG								If clinically indicated
Fasting urine phosphate and creatinine		x	x	х	х	x	x	Every cycle
TmP/GFR		x	x	х	х	x	x	Every ifosfamide
Height recorded	Х							If clinically indicated
Weight recorded	Х	х	x	х	x	х	х	Every cycle
Urine dipstick for protein/ blood	х	x	x	х	x	х	х	See algorithm

Issue Date: October 2023 Review Date October 2026	Page 7 of 11	Protocol reference: MPHAIFOET	0
Author: Rob Challoner	Authorised by: Drugs & Therapeutics Committee Version No: 1.2		Version No: 1.2



Urine Dipstick testing for inpatients receiving Ifosfamide

Pre ifosfamide (baseline test): Using medi-test combi 8 for haematuria Negative? Continue Positive? 1. What is the cause? Rule out menstruation/UTI


2. In all cases send a spot urine sample to the lab for review:



During ifosfamide infusion (excluding pump):

All patients: test urine every morning and evening for haematuria using Medi- test combi 8 strips

*A slight green discolouration of yellow test field is normal and not indicative of blood in the urine





Dose Modifications and Toxicity Management:

Haematological toxicity:

Proceed on day 1 if-

ANC ≥ 1.0 x 10 ⁹ /L	Plt ≥ 100 x 10 ⁹ /L

Delay 1 week on day 1 if-

ANC $\leq 0.9 \times 10^{9}$ /L Plt $\leq 99 \times 10^{9}$ /L
--

If platelets or ANC still below required levels for treatment at week 2, delay treatment again and patient will need assessed and chemotherapy dose reduction.

Parameter	Action	
WBC or platelets recovery >6 days	Give 80% etoposide	
Neutropenic sepsis grade 3/4	Give 80% etoposide	

If there is further bone marrow toxicity then reduce etoposide dose by a further 20%. If necessary omit etoposide completely before reducing ifosfamide.

All dose reductions must be discussed with a consultant

These haematological guidelines assume that patients are well with good performance status, that other acute toxicities have resolved and the patient has not had a previous episode of neutropenic sepsis.

Non- Haematological toxicity:

GI/mucositis	If grade 3 / 4 give 80% dose of etoposide. If there is further GI toxicity then reduce etoposide by a further 20%. If necessary omit etoposide completely rather than reduce doses of the other drugs.
Neurotoxicity	Central Observe closely for signs of encephalopathy. This may present insidiously in a variety of ways but usually includes somnolence and confusion initially. Report any early signs to medical staff immediately. Three risk factors may predispose to encephalopathy: renal impairment, low albumin, and large pelvic tumour mass. Note that most mild cases of encephalopathy will resolve spontaneously in 24 to 72 hours.

Issue Date: October 2023 Review Date October 2026	Page 9 of 11 Protocol reference: MPHAIFOETO		C
Author: Rob Challoner	Authorised by: Drugs & Therapeutics Committee Version No: 1.2		Version No: 1.2



If CTC grade 3 or 4 central neurotoxicity occurs (somnolence 30% of the time, disorientation / hallucination / coma or seizures on which consciousness is altered etc). Stop Ifosfamide infusion and give of Methylthioninium (Methylene Blue [®])
Methylthioninium 50mg in 100ml Glucose 5% over 10 mins repeated every 4 hours
Secondary prophylaxis for subsequent cycles 30 mins prior to treatment give Methylthioninium 50mg in 100ml Glucose 5% over 10 mins Repeat every 6 hours for the 3 days of ifosfamide treatment.
For further information see trust policy entitled METHYLENE BLUE® FOR IFOSFAMIDE INDUCED ENCEPHALOPATHY (IIE)

References:

Summary of Product Characteristics. *Ifofamide Injection 1g.* Baxter Healthcare Ltd. Electronic medicines compendium. [accessed on: 17/05/23] Last updated 04/04/2022

Summary of Product Characteristics. *Etoposide 20 mg/ml concentrate for solution for infusion*. Medac GmbH. Electronic medicines compendium. [accessed on: 17/05/23] Last updated 15/11/2022

Krens S D, Lassche, Jansman G F G A, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol 2019; 20: e201–08.

Goorin et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol. 2002 15;20

Circulation/Dissemination

Issue Date: October 2023 Review Date October 2026	Page 10 of 11	Protocol reference: MPHAIFOET	C
Author: Rob Challoner	Authorised by: Drugs & Therapeutics Committee Version No: 1.2		Version No: 1.2

PROTOCOL



Date added into Q-Pulse	16 th February 2024
Date document posted on the Intranet	16 th February 2024

Version History

Revision	Date	Author name and designation	Summary of main changes
1.2	26/07/2023	Anna Burke (pharmacist) Rob Challoner (pharmacist)	Renal and hepatic impairment, interactions, format, toxicities, supportive treatments Discussed with Dr Ali, Patient counselling section added, methylene blue section matched to methylblue protocol, info on renal resorption of phosphate updated, urine dipstick pathway minor corrections

Issue Date: October 2023 Review Date October 2026	Page 11 of 11	Protocol reference: MPHAIFOET	D
Author: Rob Challoner	Authorised by: Drugs & Therapeutics Committee		Version No: 1.2